Prenetics Global (NASDAQ:PRE) Reports 568% YoY Revenue Surge in Q3 2025

CHARLOTTE, N.C. — November 10, 2025 — Leads & Copy — Prenetics Global Limited (NASDAQ: PRE), a health sciences company and parent of the IM8 health and longevity brand, announced its third quarter 2025 financial results, showing a 568% year-over-year revenue surge to $23.6 million.

IM8’s monthly revenue hit a record US$9 million in October. The company’s Bitcoin treasury reached 387 BTC, valued at approximately $40 million. IM8 projects revenue of $180 – $200 million for fiscal year 2026, with $25 million monthly revenue or $300 million ARR by the end of 2026.

IM8 delivered a 60% gross margin and a 3.9-month payback period, demonstrating strong unit economics. The company will host an earnings call today at 8:30 a.m. ET and release its inaugural quarterly shareholder letter.

The record-breaking performance follows Prenetics’ $44 million equity offering in October 2025, which attracted investors including Kraken, Exodus (NYSE: EXOD), XtalPi (2228.HK), DL Holdings (1709.HK), Jihan Wu’s GPTX, and tennis champion Aryna Sabalenka. This has positioned the company for accelerated global expansion.

In October 2025, IM8 delivered approximately $9.0 million in monthly revenue, a 36% increase from September’s $6.6 million. IM8 is on track to achieve $10 million in monthly revenue by December 2025, translating to a $120 million ARR run rate in 12 months from launch. The brand has reached global scale with over 420,000 customer purchases across 31 countries. International markets now represent 56.5% of IM8’s revenue. The top five markets are:

  • United States (43.5% of revenue)
  • Canada
  • United Kingdom
  • Australia
  • Singapore

Key Performance Indicators for IM8 show the following:

  • Monthly Revenue (End of Period): Q3 2025 – $6.6 million; Q2 2025 – $4.5 million (+47%)
  • Quarterly Revenue: Q3 2025 – $17.2 million; Q2 2025 – $9.8 million (+76%)
  • Total Customer Orders: Q3 2025 – 160,000+; Q2 2025 – 90,000+ (+78%)
  • Total Servings Delivered: Q3 2025 – 4.8 million+; Q2 2025 – 2.7 million+ (+78%)
  • New Customer Average Order Value (October): $150 (October); $110 (+36%)
  • New Customer Subscription Rate: ~80%; ~80% (Maintained)
  • Gross Margin: ~60%; ~52% (+8%)
  • Payback Period: 3.9 Months; N/A (N/A)
  • Countries Served (from November): 41; 31 (+10 countries)

Danny Yeung, Chief Executive Officer and Co-Founder, said he is confident in the company’s trajectory. He noted the growth from $581,000 in monthly revenue at launch to a projected $10 million by December, a 1,600%+ increase in 12 months. Yeung also mentioned key metrics such as 36% month-over-month growth, ~80% subscription rates, $150 average order value, ~60% gross margin, and a 3.9-month customer payback period.

According to the release, the adjusted EBITDA loss has improved from $(4.5) million in Q1 2025 to $(2.1) million in Q3 2025. With approximately $120 million in total liquidity, zero debt, and the recent $44 million funding round, the company has the financial foundation to aggressively scale without dilutive capital needs. The company also believes that they can achieve $300 million ARR by year-end 2026.

Prenetics has expanded its Bitcoin treasury to 387 BTC valued at approximately $41 million and continues to execute its “1 BTC per day” accumulation strategy.

Prenetics has initiated a strategic review of non-core assets, including Europa Sports Partners, CircleDNA, and Insighta, and expects to make an announcement regarding Europa Sports Partners in the coming weeks. The company reaffirms its full-year 2025 revenue guidance of $90 to $100 million (full-year 2025 revenue for IM8 expected to be $60 million) and provides Q4 2025 revenue guidance for IM8 of $28 million, which is expected to result in a 63% quarter-over-quarter increase as compared to Q3 2025.

The Q3 2025 earnings conference call will be held today at 8:30 a.m. Eastern Time. An audio replay of the webcast will be available on the Company’s investor relations website.

The press release includes forward-looking statements with the standard disclaimer language.

Investor Relations Contact:
investors@prenetics.com
PRE@mzgroup.us 
Angela Cheung
Investor Relations / Corporate Finance
angela.hm.cheung@prenetics.com

Source: Prenetics Global Limited

×

Welcome!

BiotechReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy.

By Subscribing you will receive Daily Biotech Story Leads via email 10:30 am Mon-Fri.